secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001140361-24-005309
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore completes $402.5M convertible notes offering at 2.50% due 2030
-------------------------------------------------------------------------

- Aggregate principal $402.5M including $52.5M option exercise; net proceeds ~$389.3M.
- 2.50% interest, maturity Feb 1, 2030; initial conversion price ~$94.70/ADS (40% premium to $67.64).
- Proceeds to accelerate clinical pipeline, commercial expansion, repay Pharmakon loans, and general corporate.
- Offering upsized from $300M; sold in private placement to QIBs under Rule 144A.
- Notes redeemable after Feb 5, 2027 if ADS price >=130% of conversion price for 20 of 30 trading days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124005309/0001140361-24-005309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124005309/ef20020523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-005309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer